`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS USA, INC.,
`
`Plaintiffs,
`
`v.
`
`ELI LILLY AND COMPANY,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Case No. 1:18-cv-12029-ADB
`
`DEFENDANT ELI LILLY AND COMPANY’S MOTION
`FOR JUDGMENT AS A MATTER OF LAW UNDER FED. R. CIV. P. 50(B)
`AND/OR A NEW TRIAL UNDER FED. R. CIV. P. 59
`
`Pursuant to Fed. R. Civ. P. 50(b), Defendant Eli Lilly and Company renews its motion for
`
`judgment as a matter of law (JMOL) on three separate grounds: (1) there is no legally sufficient
`
`basis for a reasonable jury to conclude that Teva’s asserted method-of-treatment claims are
`
`adequately described; (2) there is no legally sufficient basis for a reasonable jury to conclude that
`
`Teva’s asserted method-of-treatment claims are enabled; and (3) there is no legally sufficient
`
`evidentiary basis for a reasonable jury to conclude that Teva has shown it is entitled to future lost
`
`profit damages. Lilly requests that the Court enter JMOL in Lilly’s favor on all three grounds. To
`
`the extent that the Court declines to grant JMOL in favor of Lilly on the issues of written
`
`description and enablement, Lilly also requests a new trial pursuant to Fed. R. Civ. P. 59 on those
`
`issues. The grounds for the motion are fully set forth in Lilly’s memorandum in support of this
`
`motion, filed concurrently with this motion.
`
`1
`
`
`
`Case 1:18-cv-12029-ADB Document 649 Filed 01/27/23 Page 2 of 3
`
`Dated: January 27, 2023
`
` /s/Andrea L. Martin
`Andrea L. Martin (BBO 666117)
`BURNS & LEVINSON LLP
`125 High Street
`Boston, MA 02110-1624
`(617) 345-3000
`amartin@burnslev.com
`
`William B. Raich
`Danielle A. Duszczyszyn
`Denise Main
`Pier D. DeRoo
`Matthew Luneack
`Yoonjin Lee
`Sydney Kestle
`J. Michael Jakes
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`William.Raich@finnegan.com
`Danielle.Duszczyszyn@finnegan.com
`Denise.Main@finnegan.com
`Pier.DeRoo@finnegan.com
`Matthew.Luneack@finnegan.com
`Yoonjin.Lee@finnegan.com
`Sydney.Kestle@finnegan.com
`Mike.Jakes@finnegan.com
`
`Charles E. Lipsey
`Ryan O’Quinn
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`1875 Explorer Street
`Suite 800
`Reston, VA 20190-6023
`Charles.Lipsey@finnegan.com
`Oquinnr@finnegan.com
`
`Emily R. Gabranski (BBO 694417)
`Marta Garcia Daneshvar
`Lulu Wang (BBO 704042)
`Li Zhang (BBO 708499)
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`2 Seaport Lane
`Boston, MA 02210-2001
`Emily.Gabranski@finnegan.com
`Marta.Garcia@finnegan.com
`Lulu.Wang@finnegan.com
`Li.Zhang@finnegan.com
`
`Attorneys for Defendant
`Eli Lilly and Company
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 649 Filed 01/27/23 Page 3 of 3
`
`LR 7.1(a)(2) CERTIFICATION
`
`I, Andrea Martin, hereby certify that Lilly’s counsel met and conferred with Plaintiffs’
`counsel on January 26, 2023 in an effort to narrow areas of dispute with respect to the issues
`raised in this motion.
`
`/s/ Andrea L. Martin
`Andrea L. Martin, Esq.
`
`CERTIFICATE OF SERVICE
`
`I, Andrea Martin, hereby certify that a copy of the foregoing document, filed through the
`CM/ECF system, will be sent electronically to the registered participants as identified on the
`Notice of Electronic Filing (NEF) and paper copies shall be served by first class mail postage
`prepaid on all counsel of record who are not served through the CM/ECF system on January 27,
`2023.
`
`
`/s/Andrea L. Martin
`Andrea L. Martin, Esq.
`
`